Table 2. The league table for PFS estimates interventions according to their relative effects in first part network analysis.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Apatorsen+Taxane (50.9%)# |  |  |  |  |  |  |
| -0.49 (-1.90,0.93) | Vinflunine (79%) |  |  |  |  |  |
| 0.20 (-1.09,1.49) | 0.69 (-0.73,2.11) | Vandetanib+Taxane (36.3%) |  |  |  |  |
| 0.22 (-0.68,1.13) | 0.71 (-0.38,1.80) | 0.02 (-0.90,0.94) | Taxane (31.7%) |  |  |  |
| -0.35 (-1.47,0.77) | 0.14 (-1.13,1.41) | -0.55 (-1.68,0.58) | -0.57 (-1.23,0.09) | Ramucirumab+Taxane (75.8%) |  |  |
| 0.31 (-0.98,1.60) | 0.80 (-0.63,2.22) | 0.11 (-1.19,1.41) | 0.09 (-0.83,1.01) | 0.66 (-0.47,1.79) | Pazopanib (30.4%) |  |
| 0.08 (-1.24,1.39) | 0.56 (-0.88,2.01) | -0.13 (-1.45,1.20) | -0.15 (-1.10,0.80) | 0.42 (-0.73,1.58) | -0.23 (-1.56,1.09) | Icrucumab+Taxane (45.9) |

#: The SUCRA probabilities are performed in brackets.

Abbreviations: PFS: Progression-free Survival.